The Aeson Total Artificial Heart helped three people with heart failure and pulmonary hypertension become eligible for a ...

Timothy A. Springer, a director and ten percent owner of Tectonic Therapeutic, Inc. (NASDAQ:TECX), has significantly increased his stake in the company through recent stock purchases. According to a ...

Tectonic Therapeutic (NASDAQ:TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary ...

In related news, Tectonic Therapeutics has been under scrutiny after Eli Lilly halted a phase 2 clinical trial for a drug similar to Tectonic's TX45. Despite this, Leerink Partners maintained ...

The capital is earmarked for the clinical development of Tectonic's TX45 and TX2100, as well as for enhancing their discovery platform, in addition to providing working capital and supporting ...

The capital raised will be utilized to advance the clinical development of key product candidates, TX45 and TX2100, as well as fund the discovery platform, which may accelerate the company’s ...

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction ...

Nvidia (NASDAQ: NVDA) CEO Jensen Huang’s meeting with President Donald Trump on Friday capped a whirlwind week for the increasingly life sciences-focused Silicon Valley microprocessing giant, in ...

Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed ...

Investing.com -- Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with ...

TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin.